Current Tropical Medicine Reports

, Volume 5, Issue 1, pp 51–58 | Cite as

Tuberculosis Prevention: an Under Prioritized yet Critical Intervention to Reduce Child Tuberculosis Morbidity and Mortality

  • Moorine Penninah Sekadde
  • Alexander W. Kay
Pediatric Global Health (D Nguyen and A Mandalakas, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Pediatric Global Health


Purpose of Review

Identification of vulnerable household tuberculosis (TB) contacts, particularly children under 5 years of age, has been recommended for over 10 years by the World Health Organization (WHO), but uptake has been poor in TB high-burden settings where this intervention is most needed. In part due to this failure of TB contact management, the burden of TB disease in children under 5 years of age is grossly underestimated leading to increased morbidity and mortality. In light of these unfortunate realities, it is critical to identify children exposed to TB and provide preventive treatment before they progress to active TB disease. This review highlights the role of TB prevention for children under 5 years of age and suggests strategies for improved TB prevention in high-burden settings.

Recent Findings

There have been examples of both programmatic and non-programmatic interventions that have successfully improved TB contact management and preventive therapy implementation. Here, we discuss some of these interventions and use the WHO health system building blocks to provide recommendations for improving TB prevention through isoniazid preventive therapy. Further, we describe the significant contributions of the BCG vaccine to TB prevention in young children and the need to ensure continuous supply of this critical vaccination.


Without such devotion to TB prevention, we are unlikely to meet the global END TB targets, and children under 5 years of age will continue to experience preventable morbidity and mortality secondary to TB disease.


Tuberculosis Children Prevention BCG Tuberculosis Contact Management Isoniazid 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Frigati LJ, Kranzer K, Cotton MF, Schaaf HS. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011.
  2. 2.
    Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a metaanalysis. BMC Infect Dis. 2014;14(1):1–10. CrossRefGoogle Scholar
  3. 3.
    Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ, (published 3 November 2006).
  4. 4.
    WHO. Global TB Report 2017. Geneva, 2017.Google Scholar
  5. 5.
    •• Jenkins HE, Yuen CM, Rodriguez CA, Nathavitharana RR, McLaughlin MM, Donald P, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2016;17(3):285–95. A great systematic review estimating the true burden of global child TB mortality, and the staggering degree to which it is associated with a lack of TB diagnosis. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Organization WH. The End TB Strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO, 20152016.Google Scholar
  7. 7.
    Organization WH. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. 2011.Google Scholar
  8. 8.
    Organization WH. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva; 2014.Google Scholar
  9. 9.
    Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax. 2013;68(3):247–55. Scholar
  10. 10.
    Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Enarson DA, Beyers N. Radiographic signs and symptoms in children treated for tuberculosis: possible implications for symptom-based screening in resource-limited settings. Pediatr Infect Dis J. 2006;25(3):237–40. Scholar
  11. 11.
    Kruk A, Gie RP, Schaaf HS, Marais BJ. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics. 2008;121(6):e1646–52. Scholar
  12. 12.
    Mandalakas AM, Kirchner HL, Lombard C, Walzl G, Grewal HM, Gie RP, et al. Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. Int J Tuberc Lung Dis. 2012;16(8):1033–9. Scholar
  13. 13.
    World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: WHO Press; 2015.Google Scholar
  14. 14.
    World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis; 2016 update. 2016.Google Scholar
  15. 15.
    Seddon JA, D Fred, F Amanullah, Schaaf HS, JR Starke, S Keshavjee, et al. Post-exposure management of multidrug resistant tuberculosis contacts: evidence based recommendations. Policy Brief No. 1. Dubai United Arab Emirates: Harvard Medical School Center for Global Health Delivery—Dubai. 2015.Google Scholar
  16. 16.
    Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173–80. Scholar
  17. 17.
    Harris RC, Dodd PJ, White RG. The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality. BMC Med. 2016;14(1):138. Scholar
  18. 18.
    Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PEM, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–80. CrossRefPubMedGoogle Scholar
  19. 19.
    Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ. 2000;321(7274):1435–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tchakoute CT, Hesseling AC, Kidzeru EB, Gamieldien H, Passmore JA, Jones CE, et al. Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants. J Infect Dis. 2015;211(3):338–46. Scholar
  21. 21.
    Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ (Clin Res Ed). 2014;349(aug04 5):g4643-g. Scholar
  22. 22.
    Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–8. Scholar
  23. 23.
    Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66. Scholar
  24. 24.
    Gomes VF, Andersen A, Lemvik G, Wejse C, Oliveira I, Vieira FJ, et al. Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to tuberculosis at home in Guinea-Bissau: a prospective cohort study. BMJ Open. 2013;3(3):e001545. Scholar
  25. 25.
    Luabeya KKA, Tameris MD, Geldenhuys HD, Mulenga H, Van Schalkwyk A, Hughes EJ, et al. Risk of disease after isoniazid preventive therapy for mycobacterium tuberculosis exposure in young HIV-uninfected children. Pediatr Infect Dis J. 2015;34(11):1218–22. Scholar
  26. 26.
    Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, et al. Treatment for preventing tuberculosis in children and adolescents. JAMA Pediatr. 2015;169(3):247–55. Scholar
  27. 27.
    Cruz AT, Starke JR. Safety and completion of a 4-month course of rifampin for latent tuberculous infection in children. Int J Tuberc Lung Dis. 2014;18(9):1057–61. Scholar
  28. 28.
    Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45(6):715–22. Scholar
  29. 29.
    Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the prevent tuberculosis study. Clin Infect Dis. 2015;61(4):527–35. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cruz AT, Ahmed A, Mandalakas AM, Starke JR. Treatment of latent tuberculosis infection in children. J Pediatr Infect Dis Soc. 2013;2(3):248–58. Scholar
  31. 31.
    Danyuttapolchai J, Kittimunkong S, Nateniyom S, Painujit S, Klinbuayaem V, Maipanich N, et al. Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. PLoS One. 2017;12(9):e0184986. Scholar
  32. 32.
    van Wyk SS, Reid AJ, Mandalakas AM, Enarson DA, Beyers N, Morrison J, et al. Operational challenges in managing isoniazid preventive therapy in child contacts: a high-burden setting perspective. BMC Public Health. 2011;11(1):544. Scholar
  33. 33.
    Osman M, Hesseling AC, Beyers N, Enarson DA, Rusen ID, Lombard C, et al. Routine programmatic delivery of isoniazid preventive therapy to children in Cape Town, South Africa. Public Health Action. 2013;3(3):199–203. Scholar
  34. 34.
    Claessens NJ, Gausi FF, Meijnen S, Weismuller MM, Salaniponi FM, Harries AD. Screening childhood contacts of patients with smear-positive pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis. 2002;6(4):362–4.PubMedGoogle Scholar
  35. 35.
    van Soelen N, du Preez K, van Wyk SS, Mandalakas AM, Enarson DA, Reid AJ, et al. Does an isoniazid prophylaxis register improve tuberculosis contact management in South African children? PLoS One. 2013;8(12):e80803. Scholar
  36. 36.
    Adjobimey M, Masserey E, Adjonou C, Gbenagnon G, Schwoebel V, Anagonou S, et al. Implementation of isoniazid preventive therapy in children aged under 5 years exposed to tuberculosis in Benin. Int J Tuberc Lung Dis. 2016;20(8):1055–9. Scholar
  37. 37.
    Rutherford ME, Hill PC, Triasih R, Sinfield R, van Crevel R, Graham SM. Preventive therapy in children exposed to mycobacterium tuberculosis: problems and solutions. Trop Med Int Health. 2012;17(10):1264–73. Scholar
  38. 38.
    Hill PC, Rutherford ME, Audas R, van Crevel R, Graham SM. Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries. PLoS Med. 2011;8(10):e1001105. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: a mixed-methods systematic review. PLoS One. 2017;12(8):e0182185. Scholar
  40. 40.
    Skinner D, Hesseling AC, Francis C, Mandalakas AM. It’s hard work, but it’s worth it: the task of keeping children adherent to isoniazid preventive therapy. Public Health Action. 2013;3(3):191–8. Scholar
  41. 41.
    Skinner D, Mandalakas AM. Pasting together the preventive therapy puzzle. Int J Tuberc Lung Dis. 2013;17(2):175–7. Scholar
  42. 42.
    Calnan M, Haumba S, Matsebula M, Shongwe N, Pasipamire M, Levy NK et al. Delivery of isoniazid preventive therapy to reduce occupational TB among healthcare workers in Swaziland, South Afr J Infect Dis. 2017;32(1):1–4.
  43. 43.
    Organization WH. Global tuberculosis report. 2017.Google Scholar
  44. 44.
    Organization WH. Everybody’s business: strengthening health systems to improve health outcomes, WHO’s framework for action. 2007.Google Scholar
  45. 45.
    Organization WH. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. 2010.Google Scholar
  46. 46.
    • Saunders MJ, Wingfield T, Tovar MA, Baldwin MR, Datta S, Zevallos K, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis. 2017;17(11):1190–9. A tremendous study demonstrating that risk of TB progression can be predicted among adult contacts by an exposure score. In addition, the authors clearly showed that the risk of TB progression is very high even among adult contacts in the 2 years following exposure. CrossRefPubMedGoogle Scholar
  47. 47.
    Adams LV, Olotu R, Talbot EA, Cronin BJ, Christopher R, Mkomwa Z. Ending neglect: providing effective childhood tuberculosis training for health care workers in Tanzania. Public Health Action. 2014;4(4):233–7. Scholar
  48. 48.
    Mhimbira FA, Cuevas LE, Dacombe R, Mkopi A, Sinclair D. Interventions to increase tuberculosis case detection at primary healthcare or community-level services. Cochrane Database Syst Rev. 2017;11:CD011432. Scholar
  49. 49.
    Denkinger CM, Grenier J, Stratis AK, Akkihal A, Pant-Pai N, Pai M. Mobile health to improve tuberculosis care and control: a call worth making. Int J Tuberc Lung Dis. 2013;17(6):719–27. Scholar
  50. 50.
    New fixed dose combinations for the treatment of TB in children [Internet].; 2016; [2].
  51. 51.
    van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis. 2006;10(1):13–8.PubMedGoogle Scholar
  52. 52.
    Rangaka MX, Cavalcante SC, et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet. 2015;386(10010):2344–53. Scholar
  53. 53.
    Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A. 2009;106(33):13980–5. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Moorine Penninah Sekadde
    • 1
    • 2
  • Alexander W. Kay
    • 3
    • 4
  1. 1.National Tuberculosis and Leprosy ProgramWandegeyaUganda
  2. 2.Baylor College of Medicine Children’s Foundation-UgandaKampalaUganda
  3. 3.Baylor Global Tuberculosis Program, Baylor College of MedicineHoustonUSA
  4. 4.Baylor College of Medicine, Children’s Foundation-SwazilandMbabaneSwaziland

Personalised recommendations